Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

Inclusion Criteria: * Patients must have advanced or refractory solid tumor or lymphoma (all B cell lymphomas and T cell lymphomas other than natural killer \[NK\]-cell lymphoma). * For patients in the dose expansion cohort: * Cohort A: Patients must have locally advanced, unresectable OR metastatic pancreatic cancer refractory to standard therapy. * Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. * Patients should have received previous therapy with at least one combination chemotherapy regimen for metastatic disease. * Patients with lymphoma must have exhausted or refused potential curative therapy prior to enrolling. * Weight of \>= 35 kg. * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 50%). * Hemoglobin \>= 9.0 g/dL (within 14 days prior to administration of study treatment). * Absolute neutrophil count (ANC) \>= 1,500/mcL (within 14 days prior to administration of study treatment). * Platelets \>= 100,000/mcL (within 14 days prior to administration of study treatment). * Total bilirubin =\< institutional upper limit of normal (ULN) (within 14 days prior to administration of study treatment). * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional ULN (within 14 days prior to administration of study treatment). * Serum creatinine clea…